The European Medicines Agency (EMA) issues its opinion this Tuesday on the Johnson & Johnson vaccine against Covid-19, the use of which is suspended in the United States and Europe due to the rare occurrence of serious blood clots .
The EMA, which has its headquarters in Amsterdam, must give Tuesday, a priori at 16:00, a "
virtual press conference on the conclusions about the safety assessment
" of this single-dose vaccine.
This decision is all the more important as several European countries, including France, are counting on this vaccine to speed up their immunization campaign.
Read also: Covid-19: Europe bets on vaccines to counter variants
The uncertainty on the viability of the vaccine remains unresolved, while the US health authorities last Tuesday recommended "
" in the use of Johnson & Johnson to investigate the occurrence of serious cases of blood clots in several people in the USA. However, its use should be re-authorized, perhaps accompanied by "
", and a decision should be made public by Friday, White House medical adviser Anthony Fauci said on Sunday. “
I think (vaccination) will resume, maybe with restrictions. I'm not sure what it will be, if it will be related to age or gender, or if it will just be accompanied by a warning